Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON)

• ClinicalTrials.gov Identifier: NCT01351675
• Recruitment Status: Terminated
• First Posted: May 11, 2011
• Last Update Posted: May 14, 2014
• Sponsor: Reata Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Reata Pharmaceuticals, Inc.

Tracking Information

• First Submitted Date: December 3, 2010
• First Posted Date: May 11, 2011
• Last Update Posted Date: May 14, 2014
• Study Start Date: June 2011
• Actual Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: October 18, 2012)

Time-to-first event of the composite endpoint [ Time Frame: Approximately 24 months ]

Time-to-first event of the composite endpoint consisting of:

• ESRD (need for chronic dialysis or renal transplantation)
• Cardiovascular death

Original Primary Outcome Measures (submitted: May 9, 2011)

Time-to-first event of the composite endpoint [ Time Frame: Approximately 24 months ]

Time-to-first event of the composite endpoint consisting of:

• ESRD (need for chroinic dialysis or renal transplantation)
• Cardiovascular death

Current Secondary Outcome Measures (submitted: June 21, 2011)

• Rate of change in estimated glomerular filtration rate (eGFR) over the duration of the study [ Time Frame: Approximately 24 months ]
• Time to first hospitalization for heart failure [ Time Frame: Approximately 24 months ]
• Time to first event in the composite cardiorenal endpoint [ Time Frame: Approximately 24 months ]
  Time-to-first event in the composite cardiorenal endpoint defined as:

  • Cardiovascular death
  • Non-fatal myocardial infarction
  • Non-fatal stroke
  • Hospitalization for heart failure
• Frequency, intensity, and relationship to study drug of adverse events and serious adverse events, as well as clinical and laboratory test abnormalities. [ Time Frame: Approximately 24 months ]

Original Secondary Outcome Measures (submitted: May 9, 2011)

• Rate of change in eGFR over the duration of the study [ Time Frame: Approximately 24 months ]
• Time to first hospitalization for heart failure [ Time Frame: Approximately 24 months ]
• Time to first event in the composite cardiorenal endpoint [ Time Frame: Approximately 24 months ]
  Time-to-first event in the composite cardiorenal endpoint defined as:

  • Cardiovascular death
  • Non-fatal myocardial infarction
  • Non-fatal stroke
  • Hospitalization for heart failure
• Frequency, intensity, and relationship to study drug of adverse events and serious adverse events, as well as clinical and laboratory test abnormalities. [ Time Frame: Approximately 24 months ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
• Official Title: Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
• Brief Summary: This study assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease (ESRD) and cardiovascular deaths in patients with Stage 4 Chronic Kidney Disease (CKD) and type 2 diabetes receiving standard of care.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment

Condition

• Renal Insufficiency, Chronic
• Diabetes Mellitus, Type 2

Intervention

• Drug: Placebo
  Oral, once daily
• Drug: Bardoxolone Methyl: 20 mg
  20 mg, oral, once daily
  Other Name: RTA-402

Study Arms

• Placebo Comparator: Placebo
  Intervention: Drug: Placebo
• Experimental: Bardoxolone Methyl
  Intervention: Drug: Bardoxolone Methyl: 20 mg

• Publications *: de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. Epub 2013 Nov 9.

Recruitment Information

• Recruitment Status: Terminated
• Actual Enrollment (submitted: October 18, 2012): 2185
• Original Estimated Enrollment (submitted: May 9, 2011): 1600
• Actual Study Completion Date: December 2012
• Actual Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Screening eGFR ≥ 15.0 and < 30.0 mL/min/1.73 m2;
2. A history of type 2 diabetes; diagnosis should have been made at ≥ 30 years of age;
3. Male or female at least 18 years of age;
4. Treatment with an angiotensin converting enzyme (ACE)inhibitor and/or an angiotensin II receptor blocker (ARB)for at least 6 weeks prior to and during screening. Stable dose 2 weeks prior to and during screening. Patients not taking an ACE inhibitor and/or ARB because of a medical contraindication must have discontinued treatment at least 8 weeks prior to Screening Visit A;
5. Mean systolic blood pressure (SBP) must be ≤ 160 mmHg and ≥ 105 mmHg and mean diastolic blood pressure (DBP) must be < 90 mm Hg during screening; both mean SBP and mean DBP (determined as the average of three readings) must be within this range at two separate time points measured at least 4 days apart during the screening period (blood pressure may be re-evaluated once during an unscheduled visit);
6. Willing to practice methods of birth control (both male and female patients) during the entire study period and for at least 30 days after the last dose of the study drug is ingested;
7. Serum magnesium level must be ≥ 1.3 mEq/L (0.65 mmol/L) at Screening Visit B or during subsequent unscheduled visit during screening (serum magnesium level may be re-evaluated once during an unscheduled visit);
8. Willing and able to cooperate with all aspects of the protocol;
9. Willing and able to give written informed consent for study participation and provide consent for access to medical data according to appropriate local data protection legislation, allowing authorization to access medical records and describe events captured in the endpoints

Exclusion Criteria:

1. Type 1 diabetes mellitus (juvenile onset). If a history of diabetic ketoacidosis exists, a C-peptide level must confirm type 2 diabetes;
2. Known non-diabetic renal disease (e.g., polycystic kidney disease, focal segmental glomerulosclerosis) [nephrosclerosis superimposed on diabetic kidney disease is acceptable];
3. Ongoing clinical evidence suggesting non-diabetic renal disease other than nephrosclerosis;
4. History of a renal transplant or a planned transplant from a living donor during the study;
5. Albumin to creatinine ratio (ACR) greater than 3500 mg/g (395.5 mg/mmol);
6. Hemoglobin A1c level > 11.0% (97 mmol/mol) during screening;
7. Acute dialysis or acute kidney injury within 12 weeks prior to screening or during screening;
8. Clinical signs and/or symptoms of uremia and expected need for renal replacement therapy within 12 weeks following randomization, as assessed by the investigator;
9. Recently active cardiovascular disease defined as: a. Unstable angina pectoris within 12 weeks before study randomization; b. Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before study randomization; c. Cerebrovascular accident, including transient ischemic attack within 12 weeks before study randomization; d. Current diagnosis of Class III or IV New York Heart Association (NYHA) congestive heart failure;
10. Clinical diagnosis of severe obstructive valvular heart disease or severe obstructive hypertrophic cardiomyopathy;
11. Atrioventricular block, 2o or 3o, not successfully treated with a pacemaker;
12. DAdministration of a contrast agent that may induce nephropathy within 30 days prior to study randomization or planned during the study;
13. Systemic immunosuppression for a total of > 2 weeks, cumulatively, within the 12 weeks prior to randomization or planned during the study;
14. Total bilirubin, aspartate aminotransaminase (AST) or alanine aminotransaminase (ALT) levels greater than the upper limit of normal (ULN), or alkaline phosphatase level greater than two times the ULN on ANY screening laboratory test result;
15. Female patients who are pregnant, intend to become pregnant during the study, or are nursing;
16. BMI < 18.5 g/m2
17. Known hypersensitivity to any component of the study drug;
18. Current history of drug or alcohol abuse as assessed by the investigator;
19. Clinically significant infection requiring intravenous administration of antibiotics or hospitalization within 6 weeks of screening or during screening;
20. Hepatitis B surface antigen positive;
21. Diagnosis or treatment of a malignancy in the past 5 years, excluding non-melanoma skin cancer and carcinoma in situ of the cervix or a condition highly likely to transform into malignancy during the course of the study;
22. A clinical condition that in the judgment of the investigator could potentially pose a health risk to the patient while involved in the study;
23. Participation in a clinical study involving any intervention within 30 days prior to randomization, concurrent participation in such a study, or participation in a prior clinical study involving bardoxolone methyl in any form;
24. Unable to communicate or cooperate with the investigator due to language problems, poor mental development or impaired cerebral function.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Not Provided
• Removed Location Countries: Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Israel, Italy, Mexico, Puerto Rico, Spain, Sweden, United Kingdom, United States

Administrative Information

• NCT Number: NCT01351675
• Other Study ID Numbers: 402-C-0903
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: Reata Pharmaceuticals, Inc.
• Study Sponsor: Reata Pharmaceuticals, Inc.
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Reata Pharmaceuticals, Inc.
• Verification Date: April 2014